ERBB3 and head and neck squamous cell carcinoma: Because the efficacy of EGFR inhibitors in the treatment of HNSCC is partly reduced by acquired resistance, targeting HER-3 could be a promising strategy for patients who become refractory to EGFR inhibitors.